A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Healthy Adult Male and Female Volunteers

In brief

Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.

Key facts

Study ID

NCT07413666

Run by

Centessa Pharmaceuticals (UK) Limited

People needed

212

Starts

2026-02-25

Expected to finish

2027-06-30

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy males or females as determined by assessments at the Screening Visit.
• For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening

You may not qualify if…

• Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
• History of seizure disorder, any other condition that increases the risk of seizure
• Has a clinically significant sleep disorder, including insomnia or sleep apnea

Where it is running

• Celerion — Lincoln, Nebraska, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.